Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 101 - 125 of 10290 in total

Esculin

Esculin is found in barley. Vitamin C2 is generally considered a bioflavanoid, related to vitamin P esculin is a glucoside that naturally occurs in the horse chestnut (Aesculus hippocastanum), California Buckeye (Aesculus californica) and in daphnin (the dark green resin of Daphne mezereum). Esculin belongs to the family of Glycosyl...
Approved
Matched Description: … group via a C-, S-,N-,O-, or Se- glycosidic bond. ... These are carbohydrate derivatives in which a sugar group is bonded through its anmoeric carbonA to another …

Pentobarbital

A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA...
Approved
Investigational
Vet approved
Matched Description: … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) ... It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may …
Matched Categories: … GABA Agents ... Anticholinergic Agents ... Neurotransmitter Agents ... Central Nervous System Agents …

Mirvetuximab soravtansine

Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and …
Matched Categories: … Antineoplastic Agents …

Tolbutamide

Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Description: … Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes …
Matched Categories: … Diagnostic Agents ... Blood Glucose Lowering Agents ... Hypoglycemia-Associated Agents …

Fenofibric acid

Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Categories: … Anticholesteremic Agents ... Hypolipidemic Agents ... Lipid Modifying Agents ... Agents Causing Muscle Toxicity ... Lipid Regulating Agents …

Bimatoprost

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis ... Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which …
Matched Categories: … Cardiovascular Agents ... Antihypertensive Agents …

Edetic acid

A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Matched Categories: … Chelating Agents ... Hematologic Agents ... Sequestering Agents ... Calcium Chelating Agents …

Miglustat

Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now...
Approved
Matched Description: … Miglustat was first developed as an anti-HIV agent in the 1990s. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C ... It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric …
Matched Categories: … Anti-HIV Agents ... Anti-Infective Agents ... Other Miscellaneous Therapeutic Agents …

Testosterone undecanoate

Testosterone undecanoate is the ester prodrug of testosterone and has a mid-chain fatty acid at the carbon 17β position. It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. There are oral and intramuscular formulations available for testosterone undecanoate: both formulations are indicated for...
Approved
Investigational

Exagamglogene autotemcel

Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe pain, progressive multi-organ damage, and premature death. Treatment options for SCD are largely focused on preventing the production and circulation of...
Approved
Investigational
Matched Description: … A262696,A262701] including [hydroxyurea] - a mainstay of treatment since the 1990s - as well as newer agents ... [L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States. ... It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive …

Nisoldipine

Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Description: … Nisoldipine may be used in alone or in combination with other agents in the management of hypertension …
Matched Categories: … Antiarrhythmic agents ... Antihypertensive Agents ... Agents causing hyperkalemia ... Hypotensive Agents ... Cardiovascular Agents …

Didanosine

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral...
Approved
Matched Description: … A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced …
Matched Categories: … Anti-HIV Agents ... Antiviral Agents ... Anti-Infective Agents ... Anti-Retroviral Agents ... Neurotoxic agents …

Exenatide

Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA approval on April 28, 2005 . It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand...
Approved
Investigational
Matched Description: … Bydureon BCise, an auto-injector extended-release formulation, remains available.[L42700] ... [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension …
Matched Categories: … Anti-Obesity Agents ... Blood Glucose Lowering Agents ... Hypoglycemia-Associated Agents …

Ergocalciferol

Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the...
Approved
Nutraceutical
Matched Description: … Ergocalciferol is an inactivated vitamin D analog. ... by US Pharm Holdings and was FDA approved in 1941. ... [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group …
Matched Categories: … Bone Density Conservation Agents ... Calcium-Regulating Hormones and Agents …

Niraparib

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. ... [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Bioallethrin

Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms...
Approved
Experimental
Matched Description: … Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an ... A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin …
Matched Categories: … Antiarrhythmic agents ... Agents causing hyperkalemia ... Bradycardia-Causing Agents …

Naproxen

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its...
Approved
Vet approved
Matched Description: … Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for …
Matched Categories: … Agents causing hyperkalemia ... Nephrotoxic agents ... Anti-Inflammatory Agents ... Antirheumatic Agents ... Sensory System Agents …

Saxagliptin

Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Approved
Matched Description: … FDA approved on July 31, 2009. ... Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase …
Matched Categories: … Agents causing angioedema ... Blood Glucose Lowering Agents ... Hypoglycemia-Associated Agents …

Fruquintinib

Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … [A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla ... anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. ... cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an …

Vitamin A

Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in...
Approved
Nutraceutical
Vet approved
Matched Description: … Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina …
Matched Categories: … Diagnostic Agents ... Protective Agents ... Anticarcinogenic Agents …

Bromothalonil

Bromothalonil, also known as Methyldibromo glutaronitrile (MDBGN), is a widely used preservative that can be found in many personal hygiene and industrial products. It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy . In 2005,...
Approved
Experimental
Matched Description: … most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group …

Bevacizumab

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Description: … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and ... [L12648] Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on …
Matched Categories: … Antineoplastic Agents ... Angiogenesis Modulating Agents ... Antineovascularisation Agents ... Ocular Vascular Disorder Agents ... Cardiotoxic antineoplastic agents …

Raloxifene

Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM....
Approved
Investigational
Matched Description: … [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December ... Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group ... quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents …
Matched Categories: … Bone Density Conservation Agents …

Busulfan

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought...
Approved
Investigational
Matched Categories: … Antineoplastic Agents ... Myelosuppressive Agents ... Immunosuppressive Agents ... Antineoplastic Agents, Alkylating ... Cardiotoxic antineoplastic agents …
Displaying drugs 101 - 125 of 10290 in total